A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas

British Journal of Cancer

Volumn 101, Issue 3, 2009, Pages 381-386

  Schreiber, T H ^a   Podack, E R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Immunoediting; Immunosurveillance; Methylcholanthrene

Indexed keywords

3 METHYLCHOLANTHRENE;

CHEMICAL CARCINOGENESIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOSURVEILLANCE; INCIDENCE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; SHORT SURVEY;

ANIMALS; IMMUNOLOGIC SURVEILLANCE; METHYLCHOLANTHRENE; MICE; MICE, INBRED C57BL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; SARCOMA, EXPERIMENTAL;

EID: 68149179581     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605198     Document Type: Short Survey

References (36)

1. Biggar RJ, Rabkin CS (1996) The epidemiology of AIDS-related neoplasms. Hematol Oncol Clin North Am 10: 997-1010
2. Blankenstein T, Qin Z (2003) Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. Adv Cancer Res 90: 179-207
3. Burnet M (1957) Cancer; a biological approach. I. The processes of control. Br Med J 1: 779-786
4. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168: 1356-1361
5. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, Horowitz MM, Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeni Jr JF, Boice Jr JD (1997) Solid cancers after bone marrow transplantation. N Engl J Med 336: 897-904
6. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998
7. Engel AM, Svane IM, Rygaard J, Werdelin O (1997) MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol 45: 463-470
8. Farge D (1993) Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. Eur J Med 2: 339-343
9. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NR, Raulet DH (2008) NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580
10. Haverkos HW, Drotman DP (1985) Prevalence of Kaposi's sarcoma among patients with AIDS. N Engl J Med 312: 1518
11. Hayakawa Y, Rovero S, Forni G, Smyth MJ (2003) Alpha-galactosylcer-amide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 100: 9464-9469
12. Johnston BJ (1962) Clinical effects of Coley's toxin. I. A controlled study. Cancer Chemother Rep 21: 19-41
13. Johnston BJ, Novales ET (1962) Clinical effect of Coley's toxin. II. A seven-year study. Cancer Chemother Rep 21: 43-68
14. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H (1994) Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369: 31-37
15. Kannagi M (2007) Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia. Int J Hematol 86: 113-117
16. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556-7561
17. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4: 905-913
18. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450: 903-907
19. Lagos D, Trotter MW, Vart RJ, Wang HW, Matthews NC, Hansen A, Flore O, Gotch F, Boshoff C (2007) Kaposi sarcoma herpesvirus-encoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells. Blood 109: 1550-1558
20. Luppi M, Barozzi P, Schulz TF, Setti G, Staskus K, Trovato R, Narni F, Donelli A, Maiorana A, Marasca R, Sandrini S, Torelli G (2000) Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 343: 1378-1385
21. Noguchi Y, Jungbluth A, Richards EC, Old LJ (1996) Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA 93: 11798-11801
22. Pape JW, Liautaud B, Thomas F, Mathurin JR, St Amand MM, Boncy M, Pean V, Pamphile M, Laroche AC, Johnson Jr WD (1983) Characteristics of the acquired immunodeficiency syndrome (AIDS) in Haiti. N Engl J Med 309: 945-950
23. Qin Z, Blankenstein T (2004) A cancer immunosurveillance controversy. Nat Immunol 5: 3-4; author reply 4-5
24. Qin Z, Kim HJ, Hemme J, Blankenstein T (2002) Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. J Exp Med 195: 1479-1490
25. Scadden DT (2003) AIDS-related malignancies. Annu Rev Med 54: 285-303
26. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111
27. Smyth MJ (2008) Clarification of data used in three studies on MCA-induction of sarcoma in mice. Blood 111: 4419
28. Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD (1998) An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 188: 1611-1619
29. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y (2005) NKG2D function protects the host from tumor initiation. J Exp Med 202: 583-588
30. Smyth MJ, Thia KY, Cretney E, Kelly JM, Snook MB, Forbes CA, Scalzo AA (1999) Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol 162: 6658-6662
31. Stutman O (1974) Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 183: 534-536
32. Tang ZY, Zhou HY, Zhao G, Chai LM, Zhou M, Lu JZ, Liu KD, Havas HF, Nauts HC (1991) Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma. Med Oncol Tumor Pharmacother 8: 23-28
33. van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H (1996) Decreased tumor surveillance in perforin-deficient mice. J Exp Med 184: 1781-1790
34. Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9: 684-693
35. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188: 51-64
36. Willimsky G, Czeh M, Loddenkemper C, Gellermann J, Schmidt K, Wust P, Stein H, Blankenstein T (2008) Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 205: 1687-1700